AU2016311429C1 - Modified anthrax toxin protective antigen - Google Patents

Modified anthrax toxin protective antigen Download PDF

Info

Publication number
AU2016311429C1
AU2016311429C1 AU2016311429A AU2016311429A AU2016311429C1 AU 2016311429 C1 AU2016311429 C1 AU 2016311429C1 AU 2016311429 A AU2016311429 A AU 2016311429A AU 2016311429 A AU2016311429 A AU 2016311429A AU 2016311429 C1 AU2016311429 C1 AU 2016311429C1
Authority
AU
Australia
Prior art keywords
amino acid
substituted
ser
asn
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016311429A
Other languages
English (en)
Other versions
AU2016311429A1 (en
AU2016311429B2 (en
Inventor
Thomas H. Bugge
Kuang-Hua Chen
Stephen H. Leppla
Jie Liu
Shi-Hui Liu
Diane E. PETERS
Alexander N. WEIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of AU2016311429A1 publication Critical patent/AU2016311429A1/en
Publication of AU2016311429B2 publication Critical patent/AU2016311429B2/en
Application granted granted Critical
Publication of AU2016311429C1 publication Critical patent/AU2016311429C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C07K14/325—Bacillus thuringiensis crystal peptides, i.e. delta-endotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2016311429A 2015-08-27 2016-08-25 Modified anthrax toxin protective antigen Active AU2016311429C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562210771P 2015-08-27 2015-08-27
US62/210,771 2015-08-27
US201662323218P 2016-04-15 2016-04-15
US62/323,218 2016-04-15
PCT/US2016/048706 WO2017035359A1 (en) 2015-08-27 2016-08-25 Modified anthrax toxin protective antigen

Publications (3)

Publication Number Publication Date
AU2016311429A1 AU2016311429A1 (en) 2018-04-19
AU2016311429B2 AU2016311429B2 (en) 2021-07-08
AU2016311429C1 true AU2016311429C1 (en) 2021-10-07

Family

ID=56943920

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016311429A Active AU2016311429C1 (en) 2015-08-27 2016-08-25 Modified anthrax toxin protective antigen

Country Status (7)

Country Link
US (1) US10835593B2 (https=)
EP (1) EP3341393B1 (https=)
JP (1) JP6865211B2 (https=)
KR (1) KR20180073555A (https=)
CN (1) CN108350041A (https=)
AU (1) AU2016311429C1 (https=)
WO (1) WO2017035359A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10835593B2 (en) 2015-08-27 2020-11-17 The United States Of America As Represented By The Secretary Department Of Health And Human Services Modified anthrax toxin protective antigen
AU2019379604B2 (en) 2018-11-16 2026-04-23 Rapa Therapeutics, Llc Als treatment using induced regulatory T (iTREG) cells
EP4150060A4 (en) * 2020-05-13 2024-06-19 Rapa Therapeutics, LLC TREATMENT OR PREVENTION OF PRO-INFLAMMATORY DISEASES OR CONDITIONS USING INDUCED REGULATORY T CELLS (IT)
JP7648075B2 (ja) * 2020-11-27 2025-03-18 株式会社ダイセル 融合タンパク質
CN117343942B (zh) * 2023-12-06 2024-02-13 南京市食品药品监督检验院 一种pagA重组蛋白及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101215568A (zh) * 2008-01-18 2008-07-09 丘小庆 抗炭疽多肽及其应用与制备方法
US7601351B1 (en) * 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
WO2014134187A1 (en) * 2013-02-26 2014-09-04 The Regents Of The University Of California Compositions and methods for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU771632B2 (en) 1999-09-24 2004-04-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors
WO2005090393A2 (en) 2004-02-09 2005-09-29 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Multimeric protein toxins to target cells having multiple identifying characteristics
US20100168012A1 (en) 2006-12-14 2010-07-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Human cancer therapy using engineered matrix metalloproteinase-activated anthrax lethal toxin that targets tumor vasculatuture
US9890369B2 (en) 2013-06-20 2018-02-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor
RU2016110800A (ru) * 2013-09-25 2017-10-30 Пронутриа Биосайенсис, Инк. Составы и композиции для поддержания и увеличения мышечной массы, силы и результативности, и способы их производства и использования
US10835593B2 (en) 2015-08-27 2020-11-17 The United States Of America As Represented By The Secretary Department Of Health And Human Services Modified anthrax toxin protective antigen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601351B1 (en) * 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
CN101215568A (zh) * 2008-01-18 2008-07-09 丘小庆 抗炭疽多肽及其应用与制备方法
WO2014134187A1 (en) * 2013-02-26 2014-09-04 The Regents Of The University Of California Compositions and methods for the treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mourez, Michael, et al. "Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis." Proceedings of the National Academy of Sciences 100.24 (2003): 13803-13808. *

Also Published As

Publication number Publication date
KR20180073555A (ko) 2018-07-02
AU2016311429A1 (en) 2018-04-19
US20180250376A1 (en) 2018-09-06
JP2018527926A (ja) 2018-09-27
EP3341393B1 (en) 2021-03-03
US10835593B2 (en) 2020-11-17
CN108350041A (zh) 2018-07-31
AU2016311429B2 (en) 2021-07-08
CA2996767A1 (en) 2017-03-02
JP6865211B2 (ja) 2021-04-28
WO2017035359A1 (en) 2017-03-02
EP3341393A1 (en) 2018-07-04

Similar Documents

Publication Publication Date Title
AU2016311429C1 (en) Modified anthrax toxin protective antigen
US20240092854A1 (en) Compositions and methods for targeted cytokine delivery
Bessard et al. High antitumor activity of RLI, an interleukin-15 (IL-15)–IL-15 receptor α fusion protein, in metastatic melanoma and colorectal cancer
US20120251514A1 (en) Modulated programmed death ligand-1
CA3083941A1 (en) Il-2 muteins and uses thereof
KR20150035587A (ko) 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물
CN101803492A (zh) 原核苯丙氨酸氨裂合酶的组合物及利用其组合物治疗癌症的方法
AU774419B2 (en) Inhibition of differentiation of cytotoxic T-cells by P-selectin ligand (PSGL) antagonists
JP2001508650A (ja) 新規細菌ポリペプチドおよびポリヌクレオチド
Xu et al. Impaired response to Listeria in H2-M3–deficient mice reveals a nonredundant role of MHC class Ib–specific T cells in host defense
JP7744621B2 (ja) 切断されたモルモットｌ－アスパラギナーゼバリアントおよび使用の方法
CN1711105A (zh) 治疗或预防肺炎球菌感染的组合物与方法
Peraino et al. Diphtheria toxin-based bivalent human IL-2 fusion toxin with improved efficacy for targeting human CD25+ cells
Siegall et al. Antitumor effects of interleukin 6-Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice
CA2996767C (en) Modified anthrax toxin protective antigen
WO2013039069A1 (ja) 新規な組換えｂｃｇワクチン
JPH10215882A (ja) 新規トリプトファニルｔＲＮＡシンセターゼ
HK1033956A1 (en) Genetically modified tumor-targeted bacteria with reduced virulence
HK1033956B (en) Genetically modified tumor-targeted bacteria with reduced virulence
CN121152635A (zh) 用于增强细胞疫苗的免疫原性的方法
Farr et al. Development of an HIV-1 Microbicide Based on Caulobacter crescentus: Blocking Infection
WO2010062982A1 (en) Tumor-targeting co2-resistant salmonella
JPH11103865A (ja) 新規ｓｅｒＳ
JPH11113577A (ja) 新規ｖａｌＳ
JPH11113575A (ja) 新規ｉｌｅＳ

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 25 JUN 2021

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 25 JUN 2021

FGA Letters patent sealed or granted (standard patent)